Wellington Partners

Aktiia is a company focused on providing continuous and accurate blood pressure monitoring to address hypertension, a prevalent chronic condition affecting over 1.4 billion people globally. Founded on two decades of research, Aktiia has developed a unique tool that combines optical sensors with clinically validated software algorithms to measure blood pressure at the wrist. This innovative approach enables individuals to gain insights into their blood pressure patterns and understand the underlying causes of hypertension. By delivering personalized, continuous, and medical-grade blood pressure and heart rate data, Aktiia aims to enhance patient care and empower patients, researchers, and clinicians. The company's mission is to improve the accessibility, accuracy, and actionability of blood pressure management, ultimately contributing to better health outcomes and reducing the significant mortality associated with high blood pressure.

HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, founded in 2016. It specializes in developing innovative therapies for acute and chronic liver diseases, focusing on restoring the regenerative capacity of hepatocytes. The company’s therapeutic approach is based on research led by Professor Lars Zender at the University Hospital Tübingen, which identified mitogen-activated protein kinase kinase 4 (MKK4) as a critical regulator of liver regeneration. HepaRegeniX is developing small-molecule inhibitors of MKK4, aiming to enhance liver regeneration even in severely diseased conditions. The company’s potential treatments may address various liver disorders, including nonalcoholic steatohepatitis.

Aignostics GmbH is a Berlin-based company founded in 2018 that specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics, employing patented technology to reverse-engineer conventional AI systems, thereby addressing their “black-box” limitations. Aignostics' platform generates explainable diagnostic results presented as precise heatmaps and image overlays, which facilitate the verification process for pathologists. This capability is crucial in ensuring accurate diagnoses, particularly in the context of discovering and validating biomarkers for cancer and other complex diseases. By improving the understanding of tissue-based biomarkers, Aignostics aims to significantly advance the diagnosis and treatment of various conditions, thereby supporting the broader goals of precision medicine and drug development.

CorFlow Therapeutics is a medtech startup focused on developing innovative technologies for the diagnosis and treatment of microvascular obstructions in patients experiencing heart attacks. The company has created a controlled flow infusion system that utilizes a proprietary concept to measure microvascular resistance, allowing interventional cardiologists to assess the severity of microvascular obstruction. By comparing these measurements with post-procedure contrast-enhanced magnetic resonance imaging, CorFlow's technology aims to improve the diagnosis and treatment of microvascular obstruction, potentially reducing both short- and long-term complications for severe heart attack patients. Through its advancements, CorFlow is committed to addressing significant unmet medical needs in cardiology.

Sphingotec GmbH, established in 2002 and based in Brandenburg, Germany, specializes in developing blood-based protein biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions. These conditions include acute heart failure, acute kidney injury, and circulatory shock. The company's portfolio also extends to developing monoclonal antibody therapies in combination with targeted diagnostic tests, aiming to improve the management and recovery of critically ill patients.

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company specializes in developing internal drug discovery programs focused on G-protein coupled receptors (GPCRs) to address unmet medical needs. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes the inherently unstable functional conformations of GPCRs, providing a robust framework for drug discovery. This innovative approach reveals previously inaccessible structural features of these receptors, facilitating the discovery of novel agonists and enhancing therapeutic interventions. By concentrating on stabilizing GPCRs, Confo Therapeutics aims to significantly advance the development of new treatments in the medical field.

SciRhom GmbH is a biotechnology company focused on the preclinical and early clinical development of innovative biopharmaceuticals aimed at treating life-threatening autoimmune diseases. Established in 2016 through a collaboration between experienced academic and industry scientists, the company leverages extensive research and a robust network of experts in antibody development. SciRhom specializes in creating therapeutic antibodies targeting iRhom2, a significant modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. This focus allows the company to develop improved treatment options that enhance the protection of skin and intestinal barriers, ultimately benefiting patients suffering from serious autoimmune conditions.

UroMems is a medical device company dedicated to addressing specific clinical needs related to urinary conditions that significantly impact patients' quality of life. The company specializes in the design, development, and commercialization of active implantable medical devices. Its innovative approach aims to enhance existing surgical treatments by minimizing associated side effects and ensuring that patients receive appropriate care promptly. Through its commitment to improving treatment options, UroMems seeks to benefit a wide range of patients facing urinary health challenges.

Seamless Therapeutics is a biotechnology company focused on advancing gene editing through its innovative technology platform, which specializes in the reprogramming of recombinases, a versatile class of enzymes. The company aims to transform the treatment landscape for patients with severe health conditions by providing disease-modifying product candidates that enhance the safety and precision of gene editing. By leveraging its unique approach, Seamless Therapeutics seeks to unlock new therapeutic potentials, ultimately striving to restore health and improve patient outcomes.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.

MinervaX is a biotechnology company focused on developing maternal vaccines to prevent infections caused by Group B streptococcus (GBS), which can lead to serious adverse pregnancy outcomes and life-threatening conditions for newborns. The company leverages a specific fusion protein that has shown promise in eliciting protective immunity against various clinically relevant GBS strains. By concentrating on this innovative vaccine approach, MinervaX aims to provide medical professionals with effective tools to safeguard newborns from bacterial infections, ultimately enhancing maternal and infant health outcomes.

Nyra Health is a company founded in 2020 and headquartered in Vienna, Austria, that specializes in artificial intelligence and evidence-based neurological research. It has developed a digital therapy platform aimed at addressing personal neurological deficits, which can be utilized in both clinical settings and at home using internet protocol adapters or mobile devices. This innovative platform provides a unique form of therapy grounded in scientific principles, allowing patients to maximize their rehabilitation potential regardless of time or location. Nyra Health's approach signifies a significant advancement in the field of digital rehabilitation, making therapeutic interventions more accessible and personalized for individuals with neurological challenges.

Seamless Therapeutics is a biotechnology company focused on advancing gene editing through its innovative technology platform, which specializes in the reprogramming of recombinases, a versatile class of enzymes. The company aims to transform the treatment landscape for patients with severe health conditions by providing disease-modifying product candidates that enhance the safety and precision of gene editing. By leveraging its unique approach, Seamless Therapeutics seeks to unlock new therapeutic potentials, ultimately striving to restore health and improve patient outcomes.

Nosto is a company that provides a commerce experience platform tailored for the e-commerce industry, focusing on online marketing automation. Its platform-independent software as a service (SaaS) solution enhances the online shopping experience by delivering personalized product recommendations in real-time. Designed for online retailers of all sizes, Nosto's plug-and-play technology allows for easy implementation without requiring back-end integration. This capability enables retailers to keep both product and shopper data updated in real-time, facilitating the creation, launch, and optimization of multi-channel marketing campaigns. By automating marketing activities, Nosto helps increase conversion rates, customer retention, and overall store revenues.

MinervaX is a biotechnology company focused on developing maternal vaccines to prevent infections caused by Group B streptococcus (GBS), which can lead to serious adverse pregnancy outcomes and life-threatening conditions for newborns. The company leverages a specific fusion protein that has shown promise in eliciting protective immunity against various clinically relevant GBS strains. By concentrating on this innovative vaccine approach, MinervaX aims to provide medical professionals with effective tools to safeguard newborns from bacterial infections, ultimately enhancing maternal and infant health outcomes.

Orcan Energy AG, founded in 2008 and based in Munich, Germany, specializes in developing, manufacturing, and selling energy solutions that convert waste heat into electricity using Organic Rankine Cycle (ORC) technology. The company's products, such as the PACK 20.30 and PACK 05.15 modules, are designed to reuse waste heat from various sources including industrial processes, traffic, and distributed energy conversion. These solutions have applications in marine, biogas, mobile applications like trucks, buses, construction machinery, and power generation. Orcan Energy's technology is known for its efficiency and ease of use, with innovations that make it suitable for mass market adoption. The company operates as a subsidiary of E.ON SE.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

TRiCares is a medical device company focused on creating innovative solutions for tricuspid valve regurgitation. The company specializes in developing a catheter-based valve replacement system that facilitates minimally invasive treatments for patients suffering from tricuspid insufficiency. By emphasizing anatomical conformation and user-friendly design, TRiCares aims to provide effective and durable treatment options that improve patient outcomes. Through its advancements in medical technology, TRiCares addresses a critical need in cardiology, enhancing the quality of care for those affected by this condition.

Aignostics GmbH is a Berlin-based company founded in 2018 that specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics, employing patented technology to reverse-engineer conventional AI systems, thereby addressing their “black-box” limitations. Aignostics' platform generates explainable diagnostic results presented as precise heatmaps and image overlays, which facilitate the verification process for pathologists. This capability is crucial in ensuring accurate diagnoses, particularly in the context of discovering and validating biomarkers for cancer and other complex diseases. By improving the understanding of tissue-based biomarkers, Aignostics aims to significantly advance the diagnosis and treatment of various conditions, thereby supporting the broader goals of precision medicine and drug development.

ImCheck Therapeutics is a biopharmaceutical company based in Marseille, France, that specializes in developing immunotherapeutics aimed at addressing severe unmet medical needs, particularly in the field of immuno-oncology. Founded in 2015, the company focuses on designing and developing immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules. These innovative therapies engage γ9δ2 T cells, a specific type of immune cell, to effectively treat various cancers, including breast, gastric, and ovarian cancers, as well as other solid tumors. Through its advanced research and development efforts, ImCheck Therapeutics seeks to provide next-generation immunotherapeutics for patients suffering from immune-related diseases.

Cayaba Care is a maternal health company focused on providing comprehensive support to medium and high-risk women throughout their pregnancy and postpartum journeys. The company employs a multidisciplinary approach, utilizing Maternity Navigators who are also certified doulas, to partner with members and enhance birth outcomes. Cayaba Care's services address a range of pregnancy-related concerns, including symptom relief, mental health support, breastfeeding assistance, and postpartum follow-up. By offering both virtual and in-person care, the company aims to alleviate stress and anxiety associated with pregnancy, ensuring that women experience a healthy and safe journey. Cayaba Care collaborates with commercial and Medicaid plans to implement standard and value-based care contracts, ultimately improving care quality and patient experience while achieving significant cost savings.

Sidekick is a patient-centric digital care platform designed to enhance the management and prevention of chronic and lifestyle-related conditions. By integrating evidence-based clinical approaches with behavioral economics and gamification, Sidekick's platform empowers patients to engage in personalized wellness activities. The platform facilitates multi-chronic condition management through gamified health engagement methods, health screening, and analytics, allowing users to connect with clinicians and gain valuable data insights. Sidekick collaborates with international pharmaceutical companies, payers, and healthcare providers to prioritize patient needs and improve the overall healthcare experience, making it more accessible and efficient.

Xepelin is a financial technology company focused on transforming business finance for small and medium-sized enterprises (SMEs) in Latin America. It offers a comprehensive suite of digital financial services, including short-term and long-term loans, capital credits, and accounts payable financing, all accessible through its online platform. By automating financial management and enhancing access to liquidity via smart accounts, Xepelin aims to provide economic freedom for its clients. The company also emphasizes the importance of advanced financial indicators and risk assessments to streamline decision-making within the broader business ecosystem. With a workforce of over 500 employees, Xepelin is positioned to lead a new era in finance, supported by notable investors in the industry.

UNION POS specializes in developing UNION TAB, a customizable iPad-based point of sale software tailored for bars and restaurants. Established in 2009 and headquartered in Austin, Texas, UNION POS focuses on meeting the unique needs of high-volume, high-touch venues. Their system offers a fast and intuitive interface that simplifies reporting and operational processes, allowing users to dedicate more time to customer engagement. The software includes features such as inventory management and loyalty programs, all supported by 24/7 live assistance and competitive processing fees. UNION POS aims to create a seamless experience that enhances operational efficiency while enabling businesses to concentrate on delivering exceptional service.

iOmx Therapeutics AG is a Munich-based company specializing in immuno-oncology target discovery and drug development. The company focuses on creating first-in-class cancer therapeutics that target novel immune checkpoint modulators present on tumor cells. Utilizing a proprietary siRNA-based screening technology, iOmx systematically analyzes human tumor cells to identify innovative therapeutic targets and understand their mechanisms of action. The company's approach is rooted in the principles of cancer immune-checkpoint therapy, which aims to overcome tumors' inherent resistance to immune attacks. This resistance is often mediated by cell surface molecules that inhibit T cell activation. By neutralizing these negative interactions, iOmx Therapeutics seeks to reactivate the host immune response, ultimately enhancing the effectiveness of cancer treatments.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

Automattic Inc., established in 2005 and headquartered in San Francisco, specializes in developing and providing web-based solutions. It is renowned for its suite of products, including WordPress.com for website creation and management, WooCommerce for e-commerce, and Jetpack for site performance and security. Automattic serves non-profit and open-source projects globally, with a mission to democratize publishing and commerce through its open-source content management systems.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

UroMems is a medical device company dedicated to addressing specific clinical needs related to urinary conditions that significantly impact patients' quality of life. The company specializes in the design, development, and commercialization of active implantable medical devices. Its innovative approach aims to enhance existing surgical treatments by minimizing associated side effects and ensuring that patients receive appropriate care promptly. Through its commitment to improving treatment options, UroMems seeks to benefit a wide range of patients facing urinary health challenges.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Advanced Medical Balloons is a developer of innovative medical technology specializing in custom-made balloon components designed for low and very low-pressure applications. The company focuses on advancing catheter design by utilizing microscopically thin, complex-shaped balloon films made from polyurethane. This unique technology enables the medical device industry to explore new dimensions in catheter functionality, enhancing both the efficacy and safety of medical procedures. By offering tailored solutions, Advanced Medical Balloons supports the development of cutting-edge medical devices and contributes to improved patient outcomes.

Koa Health B.V., founded in 2018 and headquartered in Amsterdam, specializes in digital healthcare solutions aimed at enhancing mental well-being in the workplace. The company, which also has offices in Barcelona, the United States, and the United Kingdom, develops a range of applications, including the koa foundation, to support employees' mental health. Koa Health's offerings incorporate the latest clinical research and technology to provide accessible and personalized mental health support across various conditions. Its product suite includes Foundations for managing mild mental health issues, Perspectives for delivering standalone cognitive-behavioral therapy (CBT) for more serious cases, and Mindset, which offers supervised digital-first CBT for patients at elevated clinical risk. Additionally, Koa Health provides a library of evidence-based activities designed to address stress, sleep improvement, relaxation, positive thinking, and self-confidence, making it a comprehensive resource for mental health prevention, prediction, and treatment.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

IconOVir Bio is a preclinical-stage biotechnology company focused on developing innovative oncolytic virus therapies for cancer treatment. The company aims to overcome the limitations associated with first- and second-generation oncolytic viruses, enhancing the ability of healthcare professionals to deliver personalized therapies tailored to individual cancer patients. Through its proprietary platform, IconOVir Bio seeks to pioneer advancements in the field of oncolytic virus therapy, ultimately improving treatment outcomes for those affected by cancer.

MinervaX is a biotechnology company focused on developing maternal vaccines to prevent infections caused by Group B streptococcus (GBS), which can lead to serious adverse pregnancy outcomes and life-threatening conditions for newborns. The company leverages a specific fusion protein that has shown promise in eliciting protective immunity against various clinically relevant GBS strains. By concentrating on this innovative vaccine approach, MinervaX aims to provide medical professionals with effective tools to safeguard newborns from bacterial infections, ultimately enhancing maternal and infant health outcomes.

Adrenomed AG is a biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for critical conditions such as sepsis and acute heart failure. Founded in 2009, the company’s lead product candidate, Adrecizumab, is a novel humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. This first-in-class treatment aims to address life-threatening situations characterized by vascular leakage and shock, offering a potential solution for patients with limited treatment options. Adrenomed employs a unique approach by combining its therapeutic antibody with a specific diagnostic tool that uses Adrenomedullin as a biomarker to identify suitable patients for treatment. The company holds a strong intellectual property position, with patents granted in major markets, ensuring its innovative therapies are well protected as they progress through clinical development.

Koa Health B.V., founded in 2018 and headquartered in Amsterdam, specializes in digital healthcare solutions aimed at enhancing mental well-being in the workplace. The company, which also has offices in Barcelona, the United States, and the United Kingdom, develops a range of applications, including the koa foundation, to support employees' mental health. Koa Health's offerings incorporate the latest clinical research and technology to provide accessible and personalized mental health support across various conditions. Its product suite includes Foundations for managing mild mental health issues, Perspectives for delivering standalone cognitive-behavioral therapy (CBT) for more serious cases, and Mindset, which offers supervised digital-first CBT for patients at elevated clinical risk. Additionally, Koa Health provides a library of evidence-based activities designed to address stress, sleep improvement, relaxation, positive thinking, and self-confidence, making it a comprehensive resource for mental health prevention, prediction, and treatment.

Sidekick is a patient-centric digital care platform designed to enhance the management and prevention of chronic and lifestyle-related conditions. By integrating evidence-based clinical approaches with behavioral economics and gamification, Sidekick's platform empowers patients to engage in personalized wellness activities. The platform facilitates multi-chronic condition management through gamified health engagement methods, health screening, and analytics, allowing users to connect with clinicians and gain valuable data insights. Sidekick collaborates with international pharmaceutical companies, payers, and healthcare providers to prioritize patient needs and improve the overall healthcare experience, making it more accessible and efficient.

UiPath Inc. specializes in designing and developing robotic process automation software for enterprises, aiming to enhance business efficiency through automation. Its comprehensive platform enables hyper-automation by identifying automation opportunities driven by artificial intelligence and human collaboration. The solution facilitates the creation, management, deployment, and optimization of automation across various business processes, including finance, healthcare, human resources, and legal operations. By utilizing a combination of robotic process automation and application programming interfaces, UiPath allows organizations to automate repetitive tasks, offering enhanced control and governance, with deployment options available both in the cloud and on-premises. Founded in 2005 and headquartered in New York, UiPath serves a diverse range of industries, including finance, insurance, telecommunications, and public sector entities.

Polares Medical S.A. is a medical device company headquartered in Ecublens, Switzerland, with an additional office in Palo Alto, California. The company specializes in developing innovative solutions for the treatment of mitral valve regurgitation. Its proprietary trans-catheter mitral valve system is designed to replace the posterior leaflet of the mitral valve with a prosthetic leaflet, allowing for hemi-replacements that improve coaptation with the native anterior leaflet. This novel approach aims to reduce or eliminate mitral valve regurgitation, addressing a significant medical need for affected patients.

UroMems is a medical device company dedicated to addressing specific clinical needs related to urinary conditions that significantly impact patients' quality of life. The company specializes in the design, development, and commercialization of active implantable medical devices. Its innovative approach aims to enhance existing surgical treatments by minimizing associated side effects and ensuring that patients receive appropriate care promptly. Through its commitment to improving treatment options, UroMems seeks to benefit a wide range of patients facing urinary health challenges.

SIRS Therapeutics is a therapeutics company focused on developing pharmaceutical drugs aimed at treating acute respiratory distress syndrome (ARDS) and systemic inflammatory response syndrome (SIRS). The company has created a fibrin-derived peptide specifically designed to assist healthcare providers in managing patients suffering from ARDS, including those with respiratory infections caused by viruses such as coronavirus. Through its innovative approach, SIRS Therapeutics seeks to enhance treatment options and improve patient outcomes in critical respiratory conditions.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

ImCheck Therapeutics is a biopharmaceutical company based in Marseille, France, that specializes in developing immunotherapeutics aimed at addressing severe unmet medical needs, particularly in the field of immuno-oncology. Founded in 2015, the company focuses on designing and developing immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules. These innovative therapies engage γ9δ2 T cells, a specific type of immune cell, to effectively treat various cancers, including breast, gastric, and ovarian cancers, as well as other solid tumors. Through its advanced research and development efforts, ImCheck Therapeutics seeks to provide next-generation immunotherapeutics for patients suffering from immune-related diseases.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Stipe Therapeutics is a biopharmaceutical company based in Aarhus C, Denmark, founded in 2018. The company specializes in developing peptide therapeutics aimed at eliminating tumors and combating cancer by harnessing the innate immune system. Stipe Therapeutics focuses on creating first-in-class drugs that target intracellular protein-protein interactions within the STING Pathway, which plays a crucial role in innate immunity and the regulation of tumorigenesis and autoimmune disorders. Through the identification and validation of compounds that sensitize the STING pathway, Stipe Therapeutics aims to modulate the tumor microenvironment, thereby enhancing the body's anti-tumoral responses and improving treatment outcomes for cancer patients.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company headquartered in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead product candidate, MV-CHIK, has completed Phase II clinical trials for chikungunya treatment. Themis is also engaged in developing vaccines for various health threats, including cancer, Zika virus, Lassa fever, and MERS. Themis leverages its advanced understanding of immune system mechanisms through its innovative vaccine platform, focusing on both emerging and specialized indications. The company has established research collaborations and exclusive licensing agreements to enhance its development capabilities, positioning itself as a strategic partner for leading biotechnology and pharmaceutical firms.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

AMBOSS GmbH is a digital platform based in Cologne, Germany, that caters to the needs of medical students and physicians. Founded in 2012, the company develops and markets a comprehensive medical study platform that offers valuable resources such as study materials and a question bank. The platform is designed to deliver medical knowledge quickly and efficiently, supporting users in their educational and professional endeavors. Originally established as MIAMED GmbH, AMBOSS has positioned itself as a physician-driven resource, enhancing the learning experience for those in the medical field.

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company specializes in developing internal drug discovery programs focused on G-protein coupled receptors (GPCRs) to address unmet medical needs. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes the inherently unstable functional conformations of GPCRs, providing a robust framework for drug discovery. This innovative approach reveals previously inaccessible structural features of these receptors, facilitating the discovery of novel agonists and enhancing therapeutic interventions. By concentrating on stabilizing GPCRs, Confo Therapeutics aims to significantly advance the development of new treatments in the medical field.

BlackBuck is a leading logistics company based in India, founded in 2015, that leverages technology to transform the trucking industry. By moving offline trucking operations online, BlackBuck connects shippers with truckers, providing a seamless platform for booking loads and facilitating payments, insurance, and financial services. The company's comprehensive solutions enhance reliability and efficiency in transportation, benefiting both truckers and shippers. BlackBuck's platform features tools for price discovery, route optimization, in-transit tracking, and timely delivery assurance, which collectively help clients improve business productivity. With a workforce of around 2,000 employees, BlackBuck has established itself as the largest trucking network in India and has garnered recognition for its innovative approach, earning awards such as CNBC-TV18's Young Turks Startup of the Year and Zee Business's Company of the Year in Logistics in 2018. The company is also featured in a case study by Harvard Business School, underscoring its impact on the logistics landscape.

UiPath Inc. specializes in designing and developing robotic process automation software for enterprises, aiming to enhance business efficiency through automation. Its comprehensive platform enables hyper-automation by identifying automation opportunities driven by artificial intelligence and human collaboration. The solution facilitates the creation, management, deployment, and optimization of automation across various business processes, including finance, healthcare, human resources, and legal operations. By utilizing a combination of robotic process automation and application programming interfaces, UiPath allows organizations to automate repetitive tasks, offering enhanced control and governance, with deployment options available both in the cloud and on-premises. Founded in 2005 and headquartered in New York, UiPath serves a diverse range of industries, including finance, insurance, telecommunications, and public sector entities.

Onfido Limited, established in 2010 and headquartered in London, specializes in digital identity verification. The company offers a SaaS solution that uses AI-based technology to verify government-issued IDs and match them with facial biometrics, ensuring users' identities are genuine. Onfido's platform is employed in various sectors, including financial services, marketplaces, gaming, and e-commerce, for applications such as KYC, user onboarding, and fraud detection. The company operates globally with offices in major cities like San Francisco, New York, Lisbon, Paris, New Delhi, and Singapore.

Snipr Biome ApS is a biotechnology company based in Copenhagen, Denmark, that focuses on developing innovative CRISPR technology for the treatment of microbial diseases. Incorporated in 2017, the company aims to revolutionize healthcare by utilizing a programmable approach to the adaptive immune system, enabling the targeted elimination of hazardous bacteria based on their specific DNA sequences. Snipr Biome's novel medicines are designed to provide health professionals with effective tools for microbiome engineering, allowing for selective targeting and destruction of harmful bacteria in vivo.

Import.io Ltd, established in 2012, is a London-based Software as a Service (SaaS) company with an additional office in Los Gatos, California. It specializes in converting unstructured web data into structured, machine-readable formats. Import.io offers a suite of products, including automated web extraction, data monitoring, visualization, and analysis tools, as well as APIs for system integration. The company also provides solutions for competitor price monitoring, MAP compliance, product matching, and customer sentiment analysis. Import.io serves over 850 customers, delivering high-quality data from millions of web sources to fuel business insights and competitive advantage.

Tonsser is a social network and utility app specifically designed for youth soccer players, allowing them to track their performance statistics and improve their skills. The platform serves as a football talent recognition tool, enabling players to build a comprehensive football resume that highlights their potential to teammates, coaches, and scouts. By fostering a community where young athletes can share their experiences and learn from one another, Tonsser aims to inspire players to enhance their game. Additionally, the platform connects talented individuals with clubs seeking new players, facilitating opportunities for youth soccer athletes to advance their careers.

Adrenomed AG is a biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for critical conditions such as sepsis and acute heart failure. Founded in 2009, the company’s lead product candidate, Adrecizumab, is a novel humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. This first-in-class treatment aims to address life-threatening situations characterized by vascular leakage and shock, offering a potential solution for patients with limited treatment options. Adrenomed employs a unique approach by combining its therapeutic antibody with a specific diagnostic tool that uses Adrenomedullin as a biomarker to identify suitable patients for treatment. The company holds a strong intellectual property position, with patents granted in major markets, ensuring its innovative therapies are well protected as they progress through clinical development.

Sphingotec GmbH, established in 2002 and based in Brandenburg, Germany, specializes in developing blood-based protein biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions. These conditions include acute heart failure, acute kidney injury, and circulatory shock. The company's portfolio also extends to developing monoclonal antibody therapies in combination with targeted diagnostic tests, aiming to improve the management and recovery of critically ill patients.

Polares Medical S.A. is a medical device company headquartered in Ecublens, Switzerland, with an additional office in Palo Alto, California. The company specializes in developing innovative solutions for the treatment of mitral valve regurgitation. Its proprietary trans-catheter mitral valve system is designed to replace the posterior leaflet of the mitral valve with a prosthetic leaflet, allowing for hemi-replacements that improve coaptation with the native anterior leaflet. This novel approach aims to reduce or eliminate mitral valve regurgitation, addressing a significant medical need for affected patients.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

TRiCares is a medical device company focused on creating innovative solutions for tricuspid valve regurgitation. The company specializes in developing a catheter-based valve replacement system that facilitates minimally invasive treatments for patients suffering from tricuspid insufficiency. By emphasizing anatomical conformation and user-friendly design, TRiCares aims to provide effective and durable treatment options that improve patient outcomes. Through its advancements in medical technology, TRiCares addresses a critical need in cardiology, enhancing the quality of care for those affected by this condition.

Mapillary AB is a Swedish company that operates an online street-level imagery platform designed to enhance and automate mapping through the use of collaboration, cameras, and computer vision. Founded in 2013 and based in Malmö, Mapillary allows users to capture street-level images using various devices, including smartphones and action cameras, which are then compiled to create a comprehensive visual representation of the world. The platform supports the generation of map data, benefiting sectors such as urban development and the automotive industry. With over 500 million images contributed globally, Mapillary provides tools for users to collect, share, and utilize street-level imagery while ensuring privacy through automatic blurring and tagging features. The company collaborates with notable clients and partners, including the World Bank and Toyota Research Institute, to further its mission of improving understanding of global locations through accessible visual data. As of June 2020, Mapillary operates as a subsidiary of Facebook, Inc.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company headquartered in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead product candidate, MV-CHIK, has completed Phase II clinical trials for chikungunya treatment. Themis is also engaged in developing vaccines for various health threats, including cancer, Zika virus, Lassa fever, and MERS. Themis leverages its advanced understanding of immune system mechanisms through its innovative vaccine platform, focusing on both emerging and specialized indications. The company has established research collaborations and exclusive licensing agreements to enhance its development capabilities, positioning itself as a strategic partner for leading biotechnology and pharmaceutical firms.

Heliatek GmbH, founded in 2006 and based in Dresden, Germany, specializes in the development and manufacture of organic photovoltaics (OPV) solutions, particularly HeliaSol and HeliaFilm. These innovative products are designed for integration into various building surfaces, including horizontal, vertical, and curved structures, making them suitable for retrofitting existing buildings as well as for new construction. Heliatek's OPV technology is characterized by its ultra-lightweight and flexible nature, contributing to environmentally friendly energy solutions. The company serves a diverse clientele, including those in the building and construction materials industry, automotive manufacturers, and suppliers, and has established strategic partnerships with firms such as AGC Glass Europe and Reckli China. With approximately 160 employees, Heliatek is at the forefront of advancing organic electronics, utilizing advanced roll-to-roll manufacturing processes in controlled environments to produce its solar films.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

glō is a venture-backed company focused on the development and commercialization of advanced LED display products using nanotechnology. The unique nanotechnology is based on 11 years of research at Lund University’s Nanometer Structure Consortium. Headed by Professor Lars Samuelson, one of the world’s leading scientists in this field, who has published more than 500 papers related to this technology. glō's first office is in Lund, Sweden, where basic material research continues for the next generation nanotechnology. glō's research and product development along with pilot fabrication operation is carried out at glō-USA in Sunnyvale, California. In 2016, glō established an Asia office in Taipei, Taiwan, one of the largest and fastest-growing regions for LED lighting and display applications. glō's technology sidesteps the technical limitations of current planar LED technology. It allows for the creation of highly efficient, stable and ultimately unique red, green, blue (RGB) emitters out of one material system. It aims to achieve the industry’s best color stability and ultimately enables the growth of red, green and blue emitters on the same wafer. Highly-efficient white LEDs with high color rendering will be possible without the need for phosphor conversion. It is the next enabling technology for advanced display, illumination and automotive applications. glō nanowire light-emitting diodes (nLEDs) are based on its proprietary hetero-structured semiconductor nanowire epitaxial growth and process technologies for which standard manufacturing equipment and materials can be utilized. glō currently holds over 175 patents across US, Europe and Asia. These patents are not subject to any cross-licensing with the LED oligopoly. The glō team is constantly strengthening its intellectual property position in this technology and related applications.

Tonsser is a social network and utility app specifically designed for youth soccer players, allowing them to track their performance statistics and improve their skills. The platform serves as a football talent recognition tool, enabling players to build a comprehensive football resume that highlights their potential to teammates, coaches, and scouts. By fostering a community where young athletes can share their experiences and learn from one another, Tonsser aims to inspire players to enhance their game. Additionally, the platform connects talented individuals with clubs seeking new players, facilitating opportunities for youth soccer athletes to advance their careers.

Latana Brand Tracking is a provider of cloud-based data technology that revolutionizes the brand tracking process. By utilizing proprietary mobile methodologies, the company focuses on collecting high-quality attitudinal data through millions of micro surveys distributed globally. This system allows for the real-time analysis of consumer attitudes, public opinion, and market trends, thereby offering valuable insights to research agencies, brands, consultancies, public institutions, and academia. Latana aims to eliminate guesswork in brand and marketing strategies, providing reliable data that empowers organizations to make informed decisions and optimize their campaigns, similar to the role Google Analytics plays in other marketing channels.

Dalia Research GmbH, founded in 2013 and based in Berlin, Germany, specializes in developing online software solutions for market and opinion research. The company offers a product called Samplive, which facilitates smart data collection through various applications, mobile websites, and social media platforms. Dalia operates in over 100 countries, utilizing the app economy and advanced data science techniques to distribute millions of micro-surveys worldwide. This approach enables the collection and analysis of real-time data on consumer attitudes, public opinion, and market trends. With a diverse team from 19 different countries, Dalia Research aims to generate insights that enhance the understanding of global audiences.

glō is a venture-backed company focused on the development and commercialization of advanced LED display products using nanotechnology. The unique nanotechnology is based on 11 years of research at Lund University’s Nanometer Structure Consortium. Headed by Professor Lars Samuelson, one of the world’s leading scientists in this field, who has published more than 500 papers related to this technology. glō's first office is in Lund, Sweden, where basic material research continues for the next generation nanotechnology. glō's research and product development along with pilot fabrication operation is carried out at glō-USA in Sunnyvale, California. In 2016, glō established an Asia office in Taipei, Taiwan, one of the largest and fastest-growing regions for LED lighting and display applications. glō's technology sidesteps the technical limitations of current planar LED technology. It allows for the creation of highly efficient, stable and ultimately unique red, green, blue (RGB) emitters out of one material system. It aims to achieve the industry’s best color stability and ultimately enables the growth of red, green and blue emitters on the same wafer. Highly-efficient white LEDs with high color rendering will be possible without the need for phosphor conversion. It is the next enabling technology for advanced display, illumination and automotive applications. glō nanowire light-emitting diodes (nLEDs) are based on its proprietary hetero-structured semiconductor nanowire epitaxial growth and process technologies for which standard manufacturing equipment and materials can be utilized. glō currently holds over 175 patents across US, Europe and Asia. These patents are not subject to any cross-licensing with the LED oligopoly. The glō team is constantly strengthening its intellectual property position in this technology and related applications.

Artfinder is an online art marketplace that connects art lovers with independent artists from over 100 countries, facilitating the purchase of authentic and affordable art. The platform features a diverse collection of more than 500,000 artworks, including paintings, photography, sculptures, and prints. By providing a space for over 10,000 artists and galleries, Artfinder supports the livelihoods of these creators and promotes the appreciation of art in everyday life. Recognized as the first Certified B Corporation in the art sector, Artfinder is committed to balancing social purpose and environmental responsibility with its business operations. With a global subscriber base exceeding 600,000, the company offers a unique opportunity for customers to enhance their homes and workplaces while fostering a sustainable art community.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company headquartered in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead product candidate, MV-CHIK, has completed Phase II clinical trials for chikungunya treatment. Themis is also engaged in developing vaccines for various health threats, including cancer, Zika virus, Lassa fever, and MERS. Themis leverages its advanced understanding of immune system mechanisms through its innovative vaccine platform, focusing on both emerging and specialized indications. The company has established research collaborations and exclusive licensing agreements to enhance its development capabilities, positioning itself as a strategic partner for leading biotechnology and pharmaceutical firms.

UroMems is a medical device company dedicated to addressing specific clinical needs related to urinary conditions that significantly impact patients' quality of life. The company specializes in the design, development, and commercialization of active implantable medical devices. Its innovative approach aims to enhance existing surgical treatments by minimizing associated side effects and ensuring that patients receive appropriate care promptly. Through its commitment to improving treatment options, UroMems seeks to benefit a wide range of patients facing urinary health challenges.

Heliatek GmbH, founded in 2006 and based in Dresden, Germany, specializes in the development and manufacture of organic photovoltaics (OPV) solutions, particularly HeliaSol and HeliaFilm. These innovative products are designed for integration into various building surfaces, including horizontal, vertical, and curved structures, making them suitable for retrofitting existing buildings as well as for new construction. Heliatek's OPV technology is characterized by its ultra-lightweight and flexible nature, contributing to environmentally friendly energy solutions. The company serves a diverse clientele, including those in the building and construction materials industry, automotive manufacturers, and suppliers, and has established strategic partnerships with firms such as AGC Glass Europe and Reckli China. With approximately 160 employees, Heliatek is at the forefront of advancing organic electronics, utilizing advanced roll-to-roll manufacturing processes in controlled environments to produce its solar films.

iOmx Therapeutics AG is a Munich-based company specializing in immuno-oncology target discovery and drug development. The company focuses on creating first-in-class cancer therapeutics that target novel immune checkpoint modulators present on tumor cells. Utilizing a proprietary siRNA-based screening technology, iOmx systematically analyzes human tumor cells to identify innovative therapeutic targets and understand their mechanisms of action. The company's approach is rooted in the principles of cancer immune-checkpoint therapy, which aims to overcome tumors' inherent resistance to immune attacks. This resistance is often mediated by cell surface molecules that inhibit T cell activation. By neutralizing these negative interactions, iOmx Therapeutics seeks to reactivate the host immune response, ultimately enhancing the effectiveness of cancer treatments.

Rigontec GmbH is a biopharmaceutical company based in Planegg, Germany, focused on developing RNA-based immunotherapeutics for cancer and viral diseases. Founded in 2014, the company is recognized for its innovative approach to immuno-oncology, particularly through its lead compound ImOl100. This compound acts as a stimulator of the immune receptor retinoic acid-inducible gene I (RIG-I), which detects viral RNA and promotes immune responses. ImOl100 serves as a minimal mimic of naturally occurring 3pRNA, a motif commonly found in viral RNAs, and aims to overcome the limitations associated with traditional cancer vaccines and checkpoint inhibitors. As of October 2017, Rigontec operates as a subsidiary of Merck & Co., enhancing its capabilities in the development of effective therapeutic options for patients.

Jellynote operates as an online platform dedicated to connecting and educating over 1 million aspiring musicians worldwide. It offers a vast library of over 400,000 songs, accessible via original video content, sheets, tabs, chords, and instrument-specific views. The platform's proprietary AI technology delivers intuitive learning experiences through artist masterclasses, tutorials, and interactive game modes. Jellynote generates revenue through premium subscriptions and advertisements, fostering a community where users can share their musical tastes and connect with one another across diverse instruments and genres. Available on smartphones and desktops, the platform aims to unite musicians globally, demonstrating music's power to bridge divides in an increasingly fragmented world.

Festicket is an online platform that enables music fans to discover and book tickets and travel packages for music festivals worldwide. It provides a comprehensive service that includes festival tickets, accommodation, and travel arrangements, creating a seamless experience for users planning their festival trips. Operating as a two-sided marketplace, Festicket features over 1,000 music festivals across 40 countries and collaborates with a network of 2,000 suppliers to offer a variety of options. The platform also incorporates technology to assist event creators in managing, promoting, and selling their events, facilitating a hassle-free experience for both festival-goers and organizers.

Tonsser is a social network and utility app specifically designed for youth soccer players, allowing them to track their performance statistics and improve their skills. The platform serves as a football talent recognition tool, enabling players to build a comprehensive football resume that highlights their potential to teammates, coaches, and scouts. By fostering a community where young athletes can share their experiences and learn from one another, Tonsser aims to inspire players to enhance their game. Additionally, the platform connects talented individuals with clubs seeking new players, facilitating opportunities for youth soccer athletes to advance their careers.

EndoStim Inc., established in 2009 and headquartered in Dallas, Texas, is a medical device company specializing in neurostimulation solutions for treating gastro-esophageal reflux disease (GERD). The company's primary product is a microstimulator that targets the lower esophageal sphincter muscle to restore normal function, providing long-term reflux control. EndoStim distributes its products globally, with a presence in Europe, Asia, and Latin America. Currently, it is conducting clinical trials to pursue FDA approval for this innovative treatment option.

Workframe is a software company specializing in workflow optimization for the commercial real estate (CRE) industry. Its web-based platform provides large corporate tenants, landlords, brokers, and service providers with enhanced visibility into their workflows. The solution offers actionable data to drive efficiency and cost savings by automating critical tasks and accelerating project delivery. Workframe's visual tools help users discover trends, collect inspiration, share ideas, and provide real-time project updates, thereby streamlining communication, improving collaboration, and proactively managing risk across various initiatives.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

Onfido Limited, established in 2010 and headquartered in London, specializes in digital identity verification. The company offers a SaaS solution that uses AI-based technology to verify government-issued IDs and match them with facial biometrics, ensuring users' identities are genuine. Onfido's platform is employed in various sectors, including financial services, marketplaces, gaming, and e-commerce, for applications such as KYC, user onboarding, and fraud detection. The company operates globally with offices in major cities like San Francisco, New York, Lisbon, Paris, New Delhi, and Singapore.

Mapillary AB is a Swedish company that operates an online street-level imagery platform designed to enhance and automate mapping through the use of collaboration, cameras, and computer vision. Founded in 2013 and based in Malmö, Mapillary allows users to capture street-level images using various devices, including smartphones and action cameras, which are then compiled to create a comprehensive visual representation of the world. The platform supports the generation of map data, benefiting sectors such as urban development and the automotive industry. With over 500 million images contributed globally, Mapillary provides tools for users to collect, share, and utilize street-level imagery while ensuring privacy through automatic blurring and tagging features. The company collaborates with notable clients and partners, including the World Bank and Toyota Research Institute, to further its mission of improving understanding of global locations through accessible visual data. As of June 2020, Mapillary operates as a subsidiary of Facebook, Inc.

Import.io Ltd, established in 2012, is a London-based Software as a Service (SaaS) company with an additional office in Los Gatos, California. It specializes in converting unstructured web data into structured, machine-readable formats. Import.io offers a suite of products, including automated web extraction, data monitoring, visualization, and analysis tools, as well as APIs for system integration. The company also provides solutions for competitor price monitoring, MAP compliance, product matching, and customer sentiment analysis. Import.io serves over 850 customers, delivering high-quality data from millions of web sources to fuel business insights and competitive advantage.

AMBOSS GmbH is a digital platform based in Cologne, Germany, that caters to the needs of medical students and physicians. Founded in 2012, the company develops and markets a comprehensive medical study platform that offers valuable resources such as study materials and a question bank. The platform is designed to deliver medical knowledge quickly and efficiently, supporting users in their educational and professional endeavors. Originally established as MIAMED GmbH, AMBOSS has positioned itself as a physician-driven resource, enhancing the learning experience for those in the medical field.

Zopa is a UK-based online marketplace lending platform, established in 2004, that connects individuals seeking unsecured loans with investors, both private and institutional. The platform offers various loan types, including car loans, debt consolidation, home improvement, and wedding loans, as well as peer-to-peer investment opportunities. Zopa facilitates these transactions, charging a fixed fee for borrowers and a 1% annual fee for lenders. The platform mitigates risk by enforcing monthly repayments, legal contracts, and diversifying investments. Zopa also provides an app for users to manage their loans, credit cards, savings, and monitor their credit scores. The company has received numerous awards for its innovative services and customer service.

4SC is a clinical-stage biopharmaceutical company focused on discovering and developing targeted, small-molecule drugs for the treatment of cancer and autoimmune diseases, particularly in areas with significant unmet medical needs. The company aims to offer innovative treatment options that enhance tolerability and efficacy, ultimately improving patients' quality of life. 4SC's drug development pipeline includes two clinical candidates, resminostat and Domatinostat, which are protected by a strong portfolio of patents. The company operates primarily in Germany and the European Union, while also generating revenue from various other countries.

Soundtrack Your Brand is a business-to-business music platform that enables small business owners to create and legally play personalized playlists in their venues. The company offers a subscription-based service that provides access to a vast commercial catalog of songs, allowing businesses to play any music they choose. This service ensures compliance with music licensing regulations while helping businesses enhance their digital media presence through curated soundtracks. By offering unlimited and customizable playlists, Soundtrack Your Brand caters to various business settings and events, ensuring an enjoyable experience for both customers and employees.

Latana Brand Tracking is a provider of cloud-based data technology that revolutionizes the brand tracking process. By utilizing proprietary mobile methodologies, the company focuses on collecting high-quality attitudinal data through millions of micro surveys distributed globally. This system allows for the real-time analysis of consumer attitudes, public opinion, and market trends, thereby offering valuable insights to research agencies, brands, consultancies, public institutions, and academia. Latana aims to eliminate guesswork in brand and marketing strategies, providing reliable data that empowers organizations to make informed decisions and optimize their campaigns, similar to the role Google Analytics plays in other marketing channels.

Dalia Research GmbH, founded in 2013 and based in Berlin, Germany, specializes in developing online software solutions for market and opinion research. The company offers a product called Samplive, which facilitates smart data collection through various applications, mobile websites, and social media platforms. Dalia operates in over 100 countries, utilizing the app economy and advanced data science techniques to distribute millions of micro-surveys worldwide. This approach enables the collection and analysis of real-time data on consumer attitudes, public opinion, and market trends. With a diverse team from 19 different countries, Dalia Research aims to generate insights that enhance the understanding of global audiences.

EyeEm is a global photography company that connects over 20 million photographers with iconic brands. It offers a platform and smartphone application that enables users to preview, purchase, and share high-quality, curated images, providing global exposure for photographers and swift, affordable access to visual content for businesses.

Rigontec GmbH is a biopharmaceutical company based in Planegg, Germany, focused on developing RNA-based immunotherapeutics for cancer and viral diseases. Founded in 2014, the company is recognized for its innovative approach to immuno-oncology, particularly through its lead compound ImOl100. This compound acts as a stimulator of the immune receptor retinoic acid-inducible gene I (RIG-I), which detects viral RNA and promotes immune responses. ImOl100 serves as a minimal mimic of naturally occurring 3pRNA, a motif commonly found in viral RNAs, and aims to overcome the limitations associated with traditional cancer vaccines and checkpoint inhibitors. As of October 2017, Rigontec operates as a subsidiary of Merck & Co., enhancing its capabilities in the development of effective therapeutic options for patients.

Onfido Limited, established in 2010 and headquartered in London, specializes in digital identity verification. The company offers a SaaS solution that uses AI-based technology to verify government-issued IDs and match them with facial biometrics, ensuring users' identities are genuine. Onfido's platform is employed in various sectors, including financial services, marketplaces, gaming, and e-commerce, for applications such as KYC, user onboarding, and fraud detection. The company operates globally with offices in major cities like San Francisco, New York, Lisbon, Paris, New Delhi, and Singapore.

Mapillary AB is a Swedish company that operates an online street-level imagery platform designed to enhance and automate mapping through the use of collaboration, cameras, and computer vision. Founded in 2013 and based in Malmö, Mapillary allows users to capture street-level images using various devices, including smartphones and action cameras, which are then compiled to create a comprehensive visual representation of the world. The platform supports the generation of map data, benefiting sectors such as urban development and the automotive industry. With over 500 million images contributed globally, Mapillary provides tools for users to collect, share, and utilize street-level imagery while ensuring privacy through automatic blurring and tagging features. The company collaborates with notable clients and partners, including the World Bank and Toyota Research Institute, to further its mission of improving understanding of global locations through accessible visual data. As of June 2020, Mapillary operates as a subsidiary of Facebook, Inc.

Hintsa is a leading evidence-based coaching company that supports athletes and business professionals in achieving sustainable success. The company employs scientifically backed methods tested in high-pressure environments, including elite sports and corporate settings. Its clients range from Formula 1 champions and Fortune 500 executives to professionals in various industries such as management consulting, healthcare, and energy. Hintsa focuses on enhancing performance and well-being, helping individuals and teams lead healthier, less stressful lives while fully engaging in their work. Recognized as a thought leader in the coaching field, Hintsa has garnered accolades from prominent organizations such as the World Economic Forum and McKinsey Quarterly.

YPlan is a mobile application that simplifies event booking, allowing users to discover and attend curated events in their city. Founded in London in February 2012, the platform connects with over 3,500 event partners globally, providing a comprehensive selection of activities for users to explore and enjoy. With a user-friendly interface, YPlan enables individuals to browse events, make instant bookings, and attend the selected activities on the same evening. The application also integrates with Apple's PassBook for seamless mobile ticketing. YPlan has gained significant popularity, boasting over 1.5 million users and receiving more than 1,000 five-star reviews on the App Store.